What is the burden of proof for tumor mutational burden in gliomas?

VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours

(2020) Eric Song et al.   NATURE

Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes

(2020) Ekaterina Friebel et al.   CELL

Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells

(2020) Florian Klemm et al.   CELL

Evaluation of glioblastoma tumor microenvironment after treatment with pembrolizumab.

(2020) Nazanin Majd et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanisms and therapeutic implications of hypermutation in gliomas

(2020) Mehdi Touat et al.   NATURE

MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence

(2020) Radhika Mathur et al.   NEURO-ONCOLOGY

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

(2020) David A. Reardon et al.   JAMA Oncology

PD-1 inhibitors: Do they have a future in the treatment of glioblastoma?

(2020) Mustafa Khasraw et al.   CLINICAL CANCER RESEARCH

Anti–PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells

(2020) Ganesh Rao et al.   CLINICAL CANCER RESEARCH

Glioma patient profiling reveals the dominant immune suppressive adenosine axis is refractory to immune function restoration

(2020) Martina Ott et al.   JCI Insight

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors

(2019) Léa Berland et al.   Journal of Thoracic Disease

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

(2019) Junfei Zhao et al.   NATURE MEDICINE

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

(2019) Timothy F. Cloughesy et al.   NATURE MEDICINE

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

(2019) Kurt A. Schalper et al.   NATURE MEDICINE

First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

(2019) Neal Ready et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer stemness, intratumoral heterogeneity, and immune response across cancers

(2019) Alex Miranda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma

(2019) Yochai Wolf et al.   CELL

1192OAssociation of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158

(2019) A Marabelle et al.   ANNALS OF ONCOLOGY

OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC

(2019) C. Langer et al.   Journal of Thoracic Oncology

OA04.01 A Phase III Randomized Study of Nivolumab/Ipilimumab vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung Cancer

(2019) L. Bazhenova et al.   Journal of Thoracic Oncology

Longitudinal molecular trajectories of diffuse glioma in adults

(2019) Floris P. Barthel et al.   NATURE

ATIM-27. TUMOR MUTATIONAL BURDEN PREDICTS RESPONSE TO ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF TRANSCRIPTIONAL AND IMMUNOLOGICAL CORRELATES

(2019) Matthias Gromeier et al.   NEURO-ONCOLOGY

Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages

(2019) J de Groot et al.   NEURO-ONCOLOGY

Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma

(2019) Sangeeta Goswami et al.   NATURE MEDICINE

T-cell Dysfunction in Glioblastoma: Applying a New Framework

(2018) Karolina I. Woroniecka et al.   CLINICAL CANCER RESEARCH

T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

(2018) Karolina Woroniecka et al.   CLINICAL CANCER RESEARCH

The Immune Landscape of Cancer

(2018) Vésteinn Thorsson et al.   IMMUNITY

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

(2018) Georgina V Long et al.   LANCET ONCOLOGY

Recurrent Glioblastoma Treated with Recombinant Poliovirus

(2018) Annick Desjardins et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti–PD-1/anti–CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+T cell trafficking

(2018) David Taggart et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles

(2018) Franz L. Ricklefs et al.   Science Advances

Expression of PD-1 by T cells in malignant glioma patients reflects exhaustion and activation

(2018) Tom B Davidson et al.   CLINICAL CANCER RESEARCH

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

(2018) Razvan Cristescu et al.   SCIENCE

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

(2017) Sydney R. Gordon et al.   NATURE

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency

(2016) Eric Bouffet et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma

(2016) Lee A. Wheeler et al.   NEURO-ONCOLOGY

PD-L1 expression in human cancers and its association with clinical outcomes

(2016) Jinming Yu et al.   OncoTargets and Therapy

PD-L1 expression and prognostic impact in glioblastoma

(2015) Edjah K. Nduom et al.   NEURO-ONCOLOGY

Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial

(2013) Manfred Westphal et al.   LANCET ONCOLOGY